Hear from us 18 November 2024 Orphelia Pharma provides update on the regulatory submission of KIZFIZO® with the European Medicines Agency Read More > 11 June 2024 ORPHELIA Pharma to collaborate with Oscar Lambret clinical center to study KIZFIZO®, the first pediatric drinkable formulation of temozolomide, for the treatment of refractory or relapsed nephroblastoma (Wilms tumor) Read More > 22 May 2024 ORPHELIA Pharma and University of Birmingham strengthen their collaboration to support the registration of KIZFIZO® Read More > 18 April 2024 Orphelia Pharma secures European patent covering KIGABEQ®, the first pediatric formulation of vigabatrin Read More > 5 March 2024 International Drug Repurposing Conference 2024, 6-7th March 2024, Barcelona Read More > 15 February 2024 ORPHELIA Pharma raises awareness for childhood cancer Read More >